Sang­amo puts down $84M to ac­quire Tx­Cell, div­ing in­to CAR-Treg space, au­toim­mune dis­eases

Look­ing to make a name for it­self out­side gene edit­ing and gene ther­a­py, Sang­amo has snapped up a pre­clin­i­cal biotech spe­cial­iz­ing in reg­u­la­to­ry T cells in an all-cash buy­out of $84 mil­lion (€72 mil­lion) on a debt- and cash-free ba­sis.

The biotech, Tx­Cell, is de­vel­op­ing a ther­a­py based on CAR-mod­i­fied Tregs for the pre­ven­tion of graft re­jec­tion in sol­id or­gan trans­plan­ta­tion, which Sang­amo is plan­ning to take to the clin­ic in 2019. That same tech­nol­o­gy, the com­pa­nies con­tend, can be used to treat a slate of au­toim­mune dis­eases from bul­lous pem­phigoid and Crohn’s dis­ease to mul­ti­ple scle­ro­sis.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER